Advances in targeted therapy of non-small cell lung cancer;Postȩpy w terapii celowanej niedrobnokomórkowego raka płuca

Advances in Clinical and Experimental Medicine

Volumn 15, Issue 6, 2006, Pages 1107-1112

  Gołecki, Marcin ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Angiogenesis; EGFR; ERB B; Non small cell lung cancer; Targeted therapy; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR BIOLOGY; MONOTHERAPY; POLAND; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TUMOR VASCULARIZATION;

RIBES;

EID: 33846674872     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Wojciechowska U, Didkowska J, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 2002 roku. Centrum Onkologii. Wyd. Instytut im. Marii Skłodowskiej-Curie, Warszawa 2004, 35-36.
2. DeVita VT, Hellman S, Rosenberg SA: Cancer principles and practice of oncology. Lippincott Williams and Wilkins, 2004, wyd. 7,925-927.
3. American Joint Committee on Cancer: AJCC Cancer staging handbook. Springer, 2002, 6th ed., 191-203.
4. Krzakowski M: Onkologia kliniczna. Borgis 2001, tom 2, wyd. 1, 13-47.
5. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trias. Br Med J 1995, 311, 899-909.
6. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A: Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of an european multicenter trial including 612 patients. J Clin Oncol 1994, 12, 360-367.
7. Woźniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR: Randomised trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998, 16, 2459-2465.
8. Bonomi P, Kim K, Fairclough D, Cella D, Kuglar J, Rowinsky E, Jiroutek M, Johnson D: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Co-operative Oncology Group trial. J Clin Oncol 2000, 18, 623-631.
9. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cornier Y, Gatzemeier U, Mattson K, Manegold C: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone In patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000, 18, 122-130.
10. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM: Randomised phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19, 3210-3218.
11. Schiller JH, Harrington D, Belani CP, Langer K, Sandler A, Krook J, Zhu J: Comparison of four chemotherapy regiments for advanced non-small cell lung cancer. N Engl J Med 2002, 346, 92-98.
12. Shepherd FA Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R: Prospective randomized trial of docetaxel versus best supportive cate in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18, 2095-2103.
13. Hanna N, Shepherd FA, Foseila FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Piess M, Muller T Lim HL: Randomised phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22, 1589-1597.
14. Perrone F, Di Maio M, Budillon A, Normanno N: Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Curr Opin Oncol 2005, 17, 2, 123-129.
15. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21, 2787-2799.
16. Castellano D: NSCLC therapy after platinum-based chemotherapy: time for a paradigm shift? Signal, 2004, 5, 2, 8-13.
17. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D Eek R, Horai T, Noda K: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003, 21, 2227-2229.
18. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani ChP, Schiller JH, Kelly K, Spiridonidis H Sandler A: Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003, 290, 2149-2158.
19. Thacher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527-1537.
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353, 2, 200-202.
21. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J: Gefitinib in combination with gerncitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004, 22, 5, 777-784.
22. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22, 5, 785-794.
23. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X Ramies D: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23, 25, 5892-5899.
24. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F: Results of phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings, J Clin Oncol 2004, 22, 14S, 7010.
25. Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 2004, 22, 5, 759-761.
26. Tsao MS, Sakurada A, Cutz JC, Zhu ChQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Whitehead M, Ding K, Pater J, Shepherd FA: Erlotinib in lung cancer - molecular and clinical predictors of outcome. NEJM 2005, 353, 133-144.
27. Harris M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004, 5, 292-302.
28. Dubey S, Schiller JH: Three emerging new drugs for NSCLC: pemetrexed, bortezomib and cetuximab. Oncologist 2005, 10, 4, 282-291.
29. Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I, Gatzemeier U: Randomised phase II study of cetuximab in combination with cisplatin (C) and vinorelbina (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growt facto receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings 2004, 22, 14S, 7012.
30. Lilenbaum R, Bonomi P, Ansari R, Lynch T, Govindan R, Janne P, Hanna N: A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results. ASCO Annual Meeting 2005, abstr. 7036. www.asco.org.
31. Thienelt ChD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K: Multicenter phase I/II study of cetuksimab with paclitaksel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005, 23, 34, 8786-8793.
32. Szostakiewicz B, Dziadziuszko R, Jassem J: Perspektywy zastosowania inhibitorów angiogenezy w leczeniu niedrobnokomórkowego raka płuca. Wsp Onkol 2003, 7, 9, 668-674.
33. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM: Randomised phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22, 11, 2184-2191.
34. Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry C, Johnson DH: Randomised phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small-cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599. ASCO Annual Meeting 2005, abstr. 4. www.asco.org.
35. Rowińska-Zakrzewska E, Szturmowicz M: Celowane leczenie raka płuca. Pneumonol Alergol Pol 2004, 72, 453-459.
36. Krzakowski M, Kowalski D: Leczenie celowane w niedrobnokomórkowym raku płuca. Medipress Onkologia 2005, 2, 3-8.